Nimotuzumab plus concurrent chemo-radiotherapy versus chemo-radiotherapy in unresectable locally advanced esophageal squamous cell carcinoma (ESCC): Interim analysis from a prospective, randomized-controlled, double-blinded, multicenter, and phase III clinical trial (NXCEL1311 Study)

MLA

Xue Meng, et al. “Nimotuzumab plus Concurrent Chemo-Radiotherapy versus Chemo-Radiotherapy in Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma (ESCC): Interim Analysis from a Prospective, Randomized-Controlled, Double-Blinded, Multicenter, and Phase III Clinical Trial (NXCEL1311 Study).” Journal of Clinical Oncology, vol. 40, June 2022, p. 4016. EBSCOhost, https://doi.org/10.1200/jco.2022.40.16_suppl.4016.

APA

Xue Meng, Anping Zheng, Jun Wang, Jianhua Wang, Guang Li, Jun Zhu, Hu Ma, Xiaodong Zhu, Anhui Shi, Chunhua Dai, Senxiang Yan, Buhai Wang, Zhongyu Qu, Chun Han, Xindong Sun, Ming Ye, Ruitai Fan, Ni yazi Huerxidan, Xiaohong Wang, & Jinming Yu. (2022). Nimotuzumab plus concurrent chemo-radiotherapy versus chemo-radiotherapy in unresectable locally advanced esophageal squamous cell carcinoma (ESCC): Interim analysis from a prospective, randomized-controlled, double-blinded, multicenter, and phase III clinical trial (NXCEL1311 Study). Journal of Clinical Oncology, 40, 4016. https://doi.org/10.1200/jco.2022.40.16_suppl.4016

Chicago

Xue Meng, Anping Zheng, Jun Wang, Jianhua Wang, Guang Li, Jun Zhu, Hu Ma, et al. 2022. “Nimotuzumab plus Concurrent Chemo-Radiotherapy versus Chemo-Radiotherapy in Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma (ESCC): Interim Analysis from a Prospective, Randomized-Controlled, Double-Blinded, Multicenter, and Phase III Clinical Trial (NXCEL1311 Study).” Journal of Clinical Oncology 40 (June): 4016. doi:10.1200/jco.2022.40.16_suppl.4016.